Cargando…

A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse

RATIONALE: Opioid use disorder (OUD) is a major epidemic in the USA. Despite evidence indicating that OUD may be particularly severe for women, preclinical models have yet to establish sex as a major factor in OUD. OBJECTIVES: Here, we examined sex differences in vulnerability to relapse following i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bakhti-Suroosh, Anousheh, Towers, Eleanor Blair, Lynch, Wendy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786148/ https://www.ncbi.nlm.nih.gov/pubmed/33404740 http://dx.doi.org/10.1007/s00213-020-05750-2

Ejemplares similares

Impact of high-access exercise prior to and during early adolescence on later vulnerability to opioid use and relapse in male rats
por: Lynch, Wendy J., et al.
Publicado: (2022)

Transcriptional Profile of Exercise-Induced Protection Against Relapse to Cocaine Seeking in a Rat Model
por: Towers, Eleanor Blair, et al.
Publicado: (2023)

Sex differences in the neuroadaptations associated with incubated cocaine-craving: A focus on the dorsomedial prefrontal cortex
por: Towers, Eleanor Blair, et al.
Publicado: (2023)

Tamoxifen Blocks the Development of Motivational Features of an Addiction-Like Phenotype in Female Rats
por: Bakhti-Suroosh, Anousheh, et al.
Publicado: (2019)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Lower buprenorphine elimination rate constant is associated with lower opioid use
por: Elarabi, Hesham Farouk, et al.
Publicado: (2022)

Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction
por: Moinaddini, Fatemeh, et al.
Publicado: (2022)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Editorial: Sex differences in the neurobiology of drug relapse vulnerability
por: Manvich, Daniel F., et al.
Publicado: (2023)

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
por: Herring, Andrew A., et al.
Publicado: (2021)

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
por: D’Onofrio, Gail, et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
por: Chambers, Laura C., et al.
Publicado: (2023)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Sex- and Dose-Dependent Differences in the Development of an Addiction-Like Phenotype Following Extended-Access Fentanyl Self-Administration
por: Towers, Eleanor Blair, et al.
Publicado: (2022)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
por: Clark, Brinton, et al.
Publicado: (2019)

Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review
por: Powell, Victoria D., et al.
Publicado: (2021)

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
por: Claypool, Anneke L., et al.
Publicado: (2023)

Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
por: Eudy‐Byrne, Rena, et al.
Publicado: (2021)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder
por: Solmeyer, Anna R., et al.
Publicado: (2022)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

Adoption of Emergency Department–Initiated Buprenorphine for Patients With Opioid Use Disorder: Secondary Analysis of a Cluster Randomized Trial
por: Gao, Evangeline, et al.
Publicado: (2023)

Corrigendum to: Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Publicado: (2022)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs
por: Keshwani, Shailina, et al.
Publicado: (2022)

Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs
por: Sue, Kimberly L., et al.
Publicado: (2023)

Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
por: Solomon, Keisha T., et al.
Publicado: (2023)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2l1lh249clei9nl336p85nsbbr